Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic, Inc. (HOLX) reported an insider equity transaction by its Chief Operating Officer on a Form 4. On 11/14/2025, the COO had 1,342 shares of common stock withheld at a price of $74.15 per share.
According to the explanation, these shares were withheld to cover tax obligations arising from the settlement of restricted stock units whose service-based vesting conditions had been met. After this tax withholding transaction, the officer directly beneficially owned 77,610 shares of Hologic common stock.
Hologic Inc. (HOLX) disclosed an insider equity transaction by its General Counsel on a Form 4. On 11/14/2025, 337 shares of Hologic common stock were disposed of at $74.15 per share under transaction code "F", meaning the shares were withheld to cover tax obligations related to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the officer directly beneficially owns 28,237 shares of Hologic common stock.
Hologic, Inc. (HOLX) reported an insider tax-withholding transaction by its Principal Accounting Officer. On 11/14/2025, the officer had 187 shares of common stock withheld, coded as an "F" transaction, at a price of $74.15 per share. This type of transaction reflects shares withheld to cover tax obligations tied to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this event, the officer beneficially owned 17,884 shares of Hologic common stock directly.
Hologic, Inc. filed its Annual Report on Form 10-K and disclosed a definitive agreement to be acquired by funds managed by Blackstone and TPG. The buyers will acquire all outstanding Hologic shares for $76.00 per share in cash, plus a non-tradable contingent value right (CVR) of up to $3.00 per share in cash, for total potential consideration of $79.00 per share. The CVR payments depend on achieving specified global revenue metrics in the Breast Health business in fiscal 2026 and 2027, and the transaction is expected to close in the first half of calendar 2026, subject to stockholder approval and regulatory and other customary conditions.
Hologic describes four main segments—Diagnostics, Breast Health, GYN Surgical and Skeletal Health—focused on women’s health through early detection and treatment. As of March 29, 2025, the aggregate market value of common stock held by non-affiliates was $13,566,017,923, and as of November 13, 2025, there were 222,905,228 common shares outstanding.
Hologic (HOLX) Chairman, President and CEO Stephen P. MacMillan reported routine equity transactions. On 11/07/2025, 50,405 shares of common stock were withheld to cover taxes at $74.10 per share tied to RSU/PSU settlements. On 11/10/2025, he received an award of 169,582 restricted stock units that vest in three equal annual installments beginning on November 10, 2025. On 11/11/2025, an additional 6,679 shares were withheld for taxes at $74.60.
Following these transactions, he beneficially owned 1,430,711 shares directly (including 1,079,673 deferred RSUs/PSUs) and 1,146,829 shares indirectly through the MacMillan Family Trust.
Hologic (HOLX) reported insider activity by its Group President, International. On 11/07/2025 and 11/11/2025, the officer had shares withheld for taxes upon settlement of performance/restricted stock units, totaling 1,420 at $74.10 and 178 at $74.60. After these events and a grant, direct holdings were 134,235 shares.
On 11/10/2025, the officer received 16,823 restricted stock units, which vest in equal installments on each of the first three anniversaries of the grant date, November 10, 2025. These RSUs settle one-for-one in Hologic common stock.
Hologic (HOLX) CFO reported equity transactions. On 11/10/2025, she received 43,741 restricted stock units that vest in three equal installments starting November 10, 2025. On 11/07/2025 and 11/11/2025, 9,427 and 1,449 shares were withheld to cover taxes upon PSU/RSU settlement at $74.1 and $74.6, respectively. After these transactions, she beneficially owns 152,068 shares, which includes 41,121 deferred RSUs/PSUs.
Hologic (HOLX) reported insider activity by its Chief Operating Officer. On November 10, 2025, the officer was granted 47,106 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. The filing also shows share withholdings to cover taxes: 3,927 shares on November 7, 2025 and 1,701 shares on November 11, 2025, both coded “F.” After the reported transactions, the officer directly owned 78,952 shares. The RSUs settle one-for-one in common stock.
Hologic (HOLX) reported insider activity by its General Counsel. On November 10, 2025, the officer received 17,496 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. Shares were withheld to cover taxes upon RSU settlement: 288 shares at $74.10 on November 7 and 406 shares at $74.60 on November 11. Following these transactions, direct ownership stood at 28,574 shares. This total includes 346 shares acquired through the employee stock purchase plan since the prior report.
Hologic, Inc. announced a governance update related to equity compensation. On November 4, 2025, the company’s Compensation Committee approved a revised form of Restricted Stock Unit (RSU) Award Agreement, adopted for fiscal 2026. The revised agreement is provided as Exhibit 10.1 to the report and incorporated by reference. This is an administrative update to the standard documentation governing future RSU grants and does not disclose financial terms or changes to award amounts.